These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12912689)

  • 1. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma.
    Mulvihill A; Budning A; Jay V; Vandenhoven C; Heon E; Gallie BL; Chan HS
    Arch Ophthalmol; 2003 Aug; 121(8):1120-4. PubMed ID: 12912689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No ocular motility complications after subtenon topotecan with fibrin sealant for retinoblastoma.
    Yousef YA; Halliday W; Chan HS; Héon E; Gallie BL; Dimaras H
    Can J Ophthalmol; 2013 Dec; 48(6):524-8. PubMed ID: 24314416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma.
    Schmack I; Hubbard GB; Kang SJ; Aaberg TM; Grossniklaus HE
    Am J Ophthalmol; 2006 Aug; 142(2):310-5. PubMed ID: 16876514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orbital fibrosis and intraocular recurrence of retinoblastoma following periocular carboplatin.
    Kim JW; Yau JW; Moshfeghi D; Fishman M
    J Pediatr Ophthalmol Strabismus; 2010 May; 47 Online():e1-4. PubMed ID: 21214147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Periocular chemotherapy for retinoblastoma: success with problems?
    Abramson DH
    Arch Ophthalmol; 2005 Jan; 123(1):128-9; author reply 129. PubMed ID: 15642840
    [No Abstract]   [Full Text] [Related]  

  • 6. In vivo intraocular distribution and safety of periocular nanoparticle carboplatin for treatment of advanced retinoblastoma in humans.
    Kalita D; Shome D; Jain VG; Chadha K; Bellare JR
    Am J Ophthalmol; 2014 May; 157(5):1109-15. PubMed ID: 24503408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery).
    Abramson DH; Dunkel IJ; Brodie SE; Marr B; Gobin YP
    Ophthalmology; 2010 Aug; 117(8):1623-9. PubMed ID: 20381868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma.
    Abramson DH; Frank CM; Dunkel IJ
    Ophthalmology; 1999 Oct; 106(10):1947-50. PubMed ID: 10519590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds.
    Smith SJ; Pulido JS; Salomão DR; Smith BD; Mohney B
    Br J Ophthalmol; 2012 Aug; 96(8):1073-7. PubMed ID: 22368261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-Arterial Chemotherapy for Retinoblastoma: A Single-Center Experience.
    Akyüz C; Kıratlı H; Şen H; Aydın B; Tarlan B; Varan A
    Ophthalmologica; 2015; 234(4):227-32. PubMed ID: 26368674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe aseptic orbital cellulitis with subtenon carboplatin for intraocular retinoblastoma.
    Shah PK; Kalpana N; Narendran V; Ramakrishnan M
    Indian J Ophthalmol; 2011; 59(1):49-51. PubMed ID: 21157073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience.
    Gobin YP; Dunkel IJ; Marr BP; Brodie SE; Abramson DH
    Arch Ophthalmol; 2011 Jun; 129(6):732-7. PubMed ID: 21320950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma.
    Zage PE; Reitman AJ; Seshadri R; Weinstein JL; Mets MB; Zeid JL; Greenwald MJ; Strauss LC; Goldman S
    Pediatr Blood Cancer; 2008 Mar; 50(3):567-72. PubMed ID: 17729249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Periocular carboplatin for retinoblastoma: long-term report (12 years) on efficacy and toxicity.
    Marr BP; Dunkel IJ; Linker A; Abramson DH
    Br J Ophthalmol; 2012 Jun; 96(6):881-3. PubMed ID: 22328819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
    Gündüz K; Günalp I; Yalçindağ N; Unal E; Taçyildiz N; Erden E; Geyik PO
    Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track.
    Munier FL; Soliman S; Moulin AP; Gaillard MC; Balmer A; Beck-Popovic M
    Br J Ophthalmol; 2012 Aug; 96(8):1084-7. PubMed ID: 22368262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management and outcome of retinoblastoma with vitreous seeds.
    Manjandavida FP; Honavar SG; Reddy VA; Khanna R
    Ophthalmology; 2014 Feb; 121(2):517-24. PubMed ID: 24572675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of intraocular retinoblastoma with vincristine and carboplatin.
    Rodriguez-Galindo C; Wilson MW; Haik BG; Merchant TE; Billups CA; Shah N; Cain A; Langston J; Lipson M; Kun LE; Pratt CB
    J Clin Oncol; 2003 May; 21(10):2019-25. PubMed ID: 12743157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors.
    Peterson EC; Elhammady MS; Quintero-Wolfe S; Murray TG; Aziz-Sultan MA
    J Neurosurg; 2011 Jun; 114(6):1603-8. PubMed ID: 21294621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction.
    Demirci H; Eagle RC; Shields CL; Shields JA
    Arch Ophthalmol; 2003 Aug; 121(8):1125-31. PubMed ID: 12912690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.